Regenxbio Inc. closed an underwritten public offering of 2,700,000 common shares, priced $65 each.

The Rockville, Md.-based developer of gene therapies raised gross proceeds of about $201.8 million.

Underwriters fully exercised their option to buy 405,000 additional shares at the offering price.

Morgan Stanley, Bank of America Merrill Lynch and Barclays acted as joint book-running managers for the offering, with Raymond James as co-manager.